Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Treatment of adrenal insufficiency in adults

Lynnette K Nieman, MD
Section Editor
André Lacroix, MD
Deputy Editor
Kathryn A Martin, MD


Primary adrenal insufficiency (Addison's disease) is due to adrenocortical disease, while secondary and tertiary adrenal insufficiency are due to disorders of the pituitary gland (adrenocorticotropic hormone [ACTH] secretion) or the hypothalamus (corticotropic-releasing hormone secretion), respectively. Primary adrenal insufficiency is associated with both cortisol and mineralocorticoid deficiency. In contrast, secondary and tertiary adrenal insufficiency are associated with cortisol, but not mineralocorticoid deficiency, because aldosterone is regulated primarily by the renin-angiotensin system, which is independent of the hypothalamus and pituitary. This distinction accounts for the different clinical presentation and management of these disorders.

The management of all forms of adrenal insufficiency is reviewed here. The causes, clinical manifestations, and diagnosis of adrenal insufficiency in adults are reviewed separately. (See "Causes of primary adrenal insufficiency (Addison's disease)" and "Clinical manifestations of adrenal insufficiency in adults" and "Diagnosis of adrenal insufficiency in adults".)


Adrenal crisis refers to acute adrenal insufficiency; it is most common in patients with primary adrenal insufficiency, but may also occur in those with secondary or tertiary adrenal insufficiency. It is a life-threatening emergency that requires immediate treatment (table 1).

In patients with primary adrenal insufficiency, the major clinical features of adrenal crisis are volume depletion and hypotension, resulting mainly from mineralocorticoid deficiency.

While secondary or tertiary adrenal insufficiency (isolated glucocorticoid deficiency) does not lead to volume depletion, it decreases vascular tone, which leads to hypotension. Thus, adrenal crisis occurs less frequently in patients with secondary or tertiary adrenal insufficiency. When they do have adrenal crisis, it tends to be during acute stress, or with acute cortisol deficiency due to pituitary infarction or after surgical cure of Cushing's syndrome. (See "Clinical manifestations of adrenal insufficiency in adults", section on 'Secondary/tertiary adrenal insufficiency'.)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 16, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Taylor RL, Grebe SK, Singh RJ. Quantitative, highly sensitive liquid chromatography-tandem mass spectrometry method for detection of synthetic corticosteroids. Clin Chem 2004; 50:2345.
  2. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:364.
  3. Derendorf H, Möllmann H, Barth J, et al. Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol 1991; 31:473.
  4. Bliesener N, Steckelbroeck S, Redel L, Klingmüller D. Dose distribution in hydrocortisone replacement therapy has a significant influence on urine free cortisol excretion. Exp Clin Endocrinol Diabetes 2003; 111:443.
  5. Fariss BL, Hane S, Shinsako J, Forsham PH. Comparison of absorption of cortisone acetate and hydrocortisone hemisuccinate. J Clin Endocrinol Metab 1978; 47:1137.
  6. Purnell JQ, Brandon DD, Isabelle LM, et al. Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab 2004; 89:281.
  7. Mah PM, Jenkins RC, Rostami-Hodjegan A, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2004; 61:367.
  8. Crown A, Lightman S. Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf) 2005; 63:483.
  9. Wichers M, Springer W, Bidlingmaier F, Klingmüller D. The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Clin Endocrinol (Oxf) 1999; 50:759.
  10. Arlt W, Allolio B. Adrenal insufficiency. Lancet 2003; 361:1881.
  11. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991; 72:39.
  12. Arafah BM. Medical management of hypopituitarism in patients with pituitary adenomas. Pituitary 2002; 5:109.
  13. Grossman AB. Clinical Review#: The diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab 2010; 95:4855.
  14. Arlt W. The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab 2009; 94:1059.
  15. Jacob, K, Trainer, PJ. Topiramate can induce hypoadrenalism in patients takingoral corticosteroid replacement. BMJ 2009; 338:1788.
  16. Riedel M, Wiese A, Schürmeyer TH, Brabant G. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. Exp Clin Endocrinol 1993; 101:106.
  17. Li Voon Chong JS, Sen J, Johnson Z, et al. Hydrocortisone replacement dosage influences intraocular pressure in patients with primary and secondary hypocortisolism. Clin Endocrinol (Oxf) 2001; 54:267.
  18. Johannsson G, Filipsson H, Bergthorsdottir R, et al. Long-acting hydrocortisone for glucocorticoid replacement therapy. Horm Res 2007; 68 Suppl 5:182.
  19. Debono M, Ross RJ, Newell-Price J. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol 2009; 160:719.
  20. Whitaker MJ, Debono M, Huatan H, et al. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. Clin Endocrinol (Oxf) 2014; 80:554.
  21. Johannsson G, Nilsson AG, Bergthorsdottir R, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 2012; 97:473.
  22. Elias AN, Gwinup G. Effects of some clinically encountered drugs on steroid synthesis and degradation. Metabolism 1980; 29:582.
  23. Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 1984; 59:1204.
  24. Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 1987; 27:437.
  25. Santen RJ, Lipton A, Kendall J. Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism. JAMA 1974; 230:1661.
  26. Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 1997; 46:255.
  27. Løvås K, Gjesdal CG, Christensen M, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009; 160:993.
  28. Florkowski CM, Holmes SJ, Elliot JR, et al. Bone mineral density is reduced in female but not male subjects with Addison's disease. N Z Med J 1994; 107:52.
  29. Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994; 120:207.
  30. Valero MA, Leon M, Ruiz Valdepeñas MP, et al. Bone density and turnover in Addison's disease: effect of glucocorticoid treatment. Bone Miner 1994; 26:9.
  31. Jódar E, Valdepeñas MP, Martinez G, et al. Long-term follow-up of bone mineral density in Addison's disease. Clin Endocrinol (Oxf) 2003; 58:617.
  32. Suliman AM, Freaney R, Smith TP, et al. The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2003; 59:380.
  33. Scott RS, Donald RA, Espiner EA. Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy. Clin Endocrinol (Oxf) 1978; 9:571.
  34. Feek CM, Ratcliffe JG, Seth J, et al. Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement. Clin Endocrinol (Oxf) 1981; 14:451.
  35. Merza Z, Rostami-Hodjegan A, Memmott A, et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2006; 65:45.
  36. Arlt W, Rosenthal C, Hahner S, Allolio B. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf) 2006; 64:384.
  37. Smith SJ, MacGregor GA, Markandu ND, et al. Evidence that patients with Addison's disease are undertreated with fludrocortisone. Lancet 1984; 1:11.
  38. Oelkers W, Diederich S, Bähr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 1992; 75:259.
  39. Jadoul M, Ferrant A, De Plaen JF, Crabbé J. Mineralocorticoids in the management of primary adrenocortical insufficiency. J Endocrinol Invest 1991; 14:87.
  40. Knowlton AI, Baer L. Cardiac failure in Addison's disease. Am J Med 1983; 74:829.
  41. Flad TM, Conway JD, Cunningham SK, McKenna TJ. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency. Clin Endocrinol (Oxf) 1996; 45:529.
  42. Alkataib, AA, Cosma, M, Elamin, MB, et al. J Clin Endocrinol Metab 2009; 94:3676.
  43. Rice SP, Agarwal N, Bolusani H, et al. Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial. J Clin Endocrinol Metab 2009; 94:1966.
  44. Srinivasan M, Irving BA, Dhatariya K, et al. Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women. J Clin Endocrinol Metab 2009; 94:761.
  45. Dhatariya KK, Greenlund LJ, Bigelow ML, et al. Dehydroepiandrosterone replacement therapy in hypoadrenal women: protein anabolism and skeletal muscle function. Mayo Clin Proc 2008; 83:1218.
  46. Salem M, Tainsh RE Jr, Bromberg J, et al. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg 1994; 219:416.
  47. Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002; 287:236.
  48. Lindsay JR, Nieman LK. The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev 2005; 26:775.
  49. O'Shaughnessy RW, Hackett KJ. Maternal Addison's disease and fetal growth retardation. A case report. J Reprod Med 1984; 29:752.
  50. Wieacker P, Alexopoulos A, DeGregorio G, Breckwoldt M. [Pregnancy in Addison's disease]. Dtsch Med Wochenschr 1989; 114:1117.
  51. BRENT F. Addison's disease and pregnancy. Am J Surg 1950; 79:645.
  52. Irvine WJ, Barnes EW. Adrenocortical insufficiency. Clin Endocrinol Metab 1972; 1:549.
  53. Burrow GN, Ferris TF. Medical Complications During Pregnancy, WB Saunders, Philadelphia 1988.
  54. Corry DB, Tuck ML. Secondary aldosteronism. Endocrinol Metab Clin North Am 1995; 24:511.
  55. Wu SJ, Tsai YL, Hsieh BS. Sequential changes in plasma renin activity and aldosterone level during pregnancy. J Formos Med Assoc 1991; 90:932.
  56. Fagundes VG, Lamas CC, Francischetti EA. Renin-angiotensin-aldosterone system in normal and hypertensive pregnancy. Response to postural stimuli. Hypertension 1992; 19:II74.
  57. Dörr HG, Heller A, Versmold HT, et al. Longitudinal study of progestins, mineralocorticoids, and glucocorticoids throughout human pregnancy. J Clin Endocrinol Metab 1989; 68:863.
  58. Funder JW. Aldosterone action: fact, failure and the future. Clin Exp Pharmacol Physiol Suppl 1998; 25:S47.
  59. Thomsen JK, Fogh-Andersen N, Jaszczak P, Giese J. Atrial natriuretic peptide (ANP) decrease during normal pregnancy as related to hemodynamic changes and volume regulation. Acta Obstet Gynecol Scand 1993; 72:103.
  61. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab 2006; 91:4849.
  62. Løvås K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison's disease. Clin Endocrinol (Oxf) 2002; 56:581.
  63. Hahner S, Loeffler M, Fassnacht M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007; 92:3912.
  64. Grant DB, Barnes ND, Moncrieff MW, Savage MO. Clinical presentation, growth, and pubertal development in Addison's disease. Arch Dis Child 1985; 60:925.
  65. Urban MD, Lee PA, Gutai JP, Migeon CJ. Androgens in pubertal males with Addison's disease. J Clin Endocrinol Metab 1980; 51:925.